Benzodiazepine Drugs Market, by Product (Long Acting Benzodiazepine {Chlordiazepoxide, Diazepam, Lorazepam, Alprazolam, Clonazepam, and Others}, Short Acting Benzodiazepine {Temazepam, Midazolam, Triazolam and Others), by Application (Anxiety Disorders, Nervousness, Sedation, Seizures, Alcohol Withdrawal and Others), by Route of Administration (Oral, Injectables, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Benzodiazepines are a group of prescription-only medicines that have a sedating/hypnotic and calming effects on the nervous system. Some of the examples of benzodiazepines that are used for the treatment of anxiety, seizures, etc. are diazepam, lorazepam, oxazepam, temazepam, and alprazolam. Most of the benzodiazepine drugs are available as generics as most of the patent are expired. The benzodiazepine are still widely recognizable under brand names such as Valium or Xanax. They come in the form of tablet and capsule forms and some are available for intravenous forms to be used in hospital settings.
Market Dynamics
Market players are engaged in facility expansion, in order to expand its manufacturing facility and product portfolio. This is expected to drive growth of the global benzodiazepine drugs market over the forecast period. For instance, in January 2018, Torrent Pharmaceuticals Ltd. acquired Bio-Pharm, Inc., a U.S.-based generic pharmaceuticals and over-the-counter (OTC) Company which also included a U.S. Food and Drug Administration (FDA) registered 75,000 sqft manufacturing facility in the U.S.
Key players are engaged in receiving approval for their products from the regulatory authorities. This is expected to drive growth of the market over the forecast period. For instance, in October 2018, Amneal Pharmaceuticals, Inc., an American biopharmaceutical company announced that a generic version of Onfi (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi (clobazam) oral suspension, 2.5 mg/mL, CIV, has been approved by the U.S. Food and Drugs Administration.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook